|Partial Close, 3/2008 ||$11.2M|
|Series B, 8/2013 |
Jacobs Investment Company
DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego.
The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).